Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Intense Treatment Regimen With Intravitreal Aflibercept Injection [Phase 1, Phase 2]
Phase 1/2 trial evaluating an intense intravitreal aflibercept treatment regimen for neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2018-11-16Clinical Trial Update: Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration [Phase 2]
Phase 2 trial update evaluating adjuvant anti-mineralocorticoid-receptor treatment for anti-VEGF refractory neovascular age-related macular …
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab [Phase 4]
Phase 4 trial update evaluating intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizuma…
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
This completed clinical trial reports real-world outcomes of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration…
-
CLINICAL_TRIALS trial_result · 2018-05-09Clinical Trial Update: Study of DS-7080a for the Treatment of Macular Degeneration [Phase 1]
A Phase 1 clinical trial evaluating DS-7080a for neovascular age-related macular degeneration and diabetic macular edema has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-04-20Clinical Trial Update: Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept [Phase 4]
Phase 4 clinical trial update evaluating a two-week retreatment interval for neovascular age-related macular degeneration that is refractory…
-
CLINICAL_TRIALS trial_result · 2018-04-19Clinical Trial Update: Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration [Phase 4]
This is a Phase 4 clinical trial evaluating fixed monthly dosing of ranibizumab for neovascular age-related macular degeneration. The study …
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Neovascular Age-related Macular Degeneration
Clinical trial investigating neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration [Phase 1]
Phase 1 study evaluating multiple intravitreal injections of TK001 for neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2018-03-01Clinical Trial Update: Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration [Phase 1]
Phase 1 trial entry evaluating pharmacokinetics, safety, and tolerability of TK001 in patients with neovascular age-related macular degenera…
-
CLINICAL_TRIALS trial_result · 2018-02-12Clinical Trial Update: Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) [Phase 4]
Phase 4 trial updating efficacy and safety of ranibizumab 0.5 mg given in two alternative dosing regimens in Chinese patients with neovascul…
-
CLINICAL_TRIALS trial_result · 2018-01-08Clinical Trial Update: Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration [Phase 2]
Phase 2 dose-ranging study of pazopanib for neovascular age-related macular degeneration has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-12-02Clinical Trial Update: Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration [Phase 4]
This report summarizes the functional and structural outcomes from a Phase 4 trial examining neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2017-11-09Clinical Trial Update: A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration [Phase 1]
The document reports the completion of a Phase 1 study evaluating pazopanib tablets in patients with neovascular age-related macular degener…
-
CLINICAL_TRIALS trial_result · 2017-10-19Clinical Trial Update: Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
A completed clinical trial evaluated the effects of aflibercept on human corneal endothelial cells in neovascular age-related macular degene…
-
CLINICAL_TRIALS trial_result · 2017-09-29Clinical Trial Update: Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration [Phase 2]
This Phase 2 trial update summarizes safety and pharmacokinetics data for RTH258 (brolucizumab) in subjects with neovascular age-related mac…
-
CLINICAL_TRIALS trial_result · 2017-09-28Clinical Trial Update: To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD [Phase 2]
Phase 2 clinical trial update evaluating the pharmacodynamics, safety, and pharmacokinetics of pazopanib eye drops in adults with neovascula…
-
CLINICAL_TRIALS trial_result · 2017-08-21Clinical Trial Update: 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD) [Phase 2]
Phase 2 clinical trial update for neovascular age-related macular degeneration; the study was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2017-07-26Clinical Trial Update: A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS) [Phase 3]
Phase 3 trial update evaluating the usability of ranibizumab prefilled syringe in patients with neovascular AMD or macular edema due to reti…
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: The Evolution of Visual Acuity Measured by Electronic Tablet / Computer of Exudative AMD Patients [NA]
This clinical trial update examines changes in visual acuity over time in patients with exudative age-related macular degeneration, measured…
-
CLINICAL_TRIALS trial_result · 2017-04-27Clinical Trial Update: Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of Squalamine ophthalmic solution in neovascular age-related macular degeneration.…
-
CLINICAL_TRIALS trial_result · 2017-01-02Clinical Trial Update: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration [Phase 3]
Phase 3 trial evaluating two dosing regimens of 0.5 mg ranibizumab injections for neovascular age-related macular degeneration reported effi…
-
CLINICAL_TRIALS trial_result · 2016-11-21Clinical Trial Update: Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START [Phase 4]
This clinical trial update reports completion of a Phase 4 study evaluating early SD-OCT changes after starting intravitreal aflibercept (EY…
-
CLINICAL_TRIALS trial_result · 2016-11-04Clinical Trial Update: Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD [Phase 4]
Phase 4 clinical trial evaluating the safety and efficacy of two regimens of intravitreal ranibizumab 0.5 mg in Chinese patients with neovas…
-
CLINICAL_TRIALS trial_result · 2016-09-08Clinical Trial Update: Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration [Phase 2]
A Phase 2 trial evaluating regorafenib eye drops for neovascular age-related macular degeneration was terminated, with results posted in 201…